Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

Gregory A. Wiseman, Thomas E. Witzig

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Fingerprint

Dive into the research topics of 'Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences